More recently, adjuvant pembrolizumab has resulted in a 35% reduction in the risk of melanoma recurrence amongst patients with resected Stage IIB/IIC disease and leading to regulatory approval of anti-PD1 in this disease indication [16]. The gene discussed is PDCD1; the disease is melanoma.